MedTrace Logo

Refractory Status Epilepticus Treatment Study

NCT01586208 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2013-03-12

No results posted yet for this study

Summary

Identify the most effective dose of valproic acid when used in combination with phenytoin for treatment of patients with refractory status epilepticus, which allow a better clinical course and prognosis of the disease.

Conditions

  • Grand Mal Status Epilepticus
  • Non-convulsive Status Epilepticus

Interventions

DRUG

valproic acid (VPA)

Best dosage at the initial bolus of VPA in patient with satatus epilepticus refractarius (after benzodiazepine + phenytoin treatment)

Sponsors & Collaborators

  • Hospital Vall d'Hebron

    collaborator OTHER

  • Germans Trias i Pujol Hospital

    collaborator OTHER

  • Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

    collaborator OTHER

  • Hospital Clinic of Barcelona

    collaborator OTHER

  • Hospital Universitari de Bellvitge

    lead OTHER

Principal Investigators

  • Mercè Falip, MD · Hospital Universitari de Bellvitge

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-05-31
Completion
2012-10-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01586208 on ClinicalTrials.gov